Navigation Links
New indicator found for rapidly progressing form of deadly lung disease
Date:11/10/2010

ANN ARBOR, Mich. A diagnosis of idiopathic pulmonary fibrosis is not much better than a death sentence, given a survival rate averaging 4 to 6 years as the disease robs its victim of the ability to breathe.

But researchers at the University of Michigan have discovered a receptor in the immune system that may serve as a marker for a rapidly progressing form of the disease, which causes the body to produce excess fibrous tissue in the lungs.

More than just signaling which patients have the more aggressive form of IPF a disease that claims about as many lives each year as breast cancer the researchers hope that targeting the TLR9 receptor may lead to new treatments that could slow or stop the illness' progression. The findings were published in the Nov. 10 issue of Science Translational Medicine.

"This finding has the potential to allow physicians caring for IPF patients to better determine the natural history of disease in individual patients, which could markedly facilitate decision making for the patient and their doctors," says pulmonologist Fernando J. Martinez, M.D., M.S., a professor of internal medicine at the University of Michigan Medical School and one of the study's two senior authors. "Moreover, it opens the potential for unique therapeutic approaches."

There is no known cause, cure, or FDA-approved treatment for IPF, and it remains virtually unknown to the general public, even though it is several times more common than cystic fibrosis and Lou Gehrig's Disease (or ALS), according to the Coalition for Pulmonary Fibrosis. Moreover, IPF only receives a fraction of the funding of those higher profile conditions.

The U-M led research, which drew on expertise from the Departments of Pathology, Internal Medicine and Radiology, found that TLR9, which stands for Toll-like receptor number 9, causes an increase in the growth of fibrotic tissue in the lungs when it recognizes a particular type of DNA frequently found in bacteria and viruses. Higher amounts of TLR9 were found in patients with rapidly progressing IPF than those with slowly progressing IPF.

The researchers also peered into the workings of IPF by transplanting the disease from humans into mice. Those experiments showed a greater fibrotic response to the TLR9-activating DNA using lung cells from patients with rapidly progressing IPF than with cells from people with slowly progressing IPF.

For more than two decades, the National Institutes of Health has funded the U-M group's investigation into the biological basis of IPF as well as novel ways to diagnose and treat patients who suffer from the devastating disorder. U-M's scientists and doctors study human cells to better understand how they are involved in the progressive scarring of the lungs. In addition, clinical testing is used to help better predict the stage of disease and the rate of progression in advising patients for therapy.

"The approach taken by our group really highlights the advantages of translational research in a complex human disease and shows the bench-to-bedside model is really a two-way street," notes Cory M. Hogaboam, Ph.D., a professor of pathology at U-M and the study's other senior investigator.


'/>"/>

Contact: Ian Demsky
idemsky@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
2. A new indicator of poor prognosis in node-negative colorectal cancer patients
3. Recurrence of breast cancer after more than 10 years is an important indicator of survival
4. Definitive diabetes indicator deceptively high in African-American children
5. 3M and Maryland Hospital Association's Quality Indicator Project Partner to Deliver Comprehensive Quality Solution
6. Study finds respiratory symptoms more reliable indicator of H1N1, not fever alone
7. Visual pattern preference may be indicator of autism in toddlers
8. One-third of antimalarial medicines sampled in 3 African nations found to be substandard
9. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
10. Highmark Foundation Awards $120,000 to the American Heart Association
11. Stuttering Foundation Hails New Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 26, 2017 , ... MYOLYN, a medical technology company dedicated ... received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for two ... devices are stationary cycling systems that use MYOLYN’s patent-pending functional electrical stimulation ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... A stressful ... at work can also decrease overall productivity and performance in the workplace. The goal ... , During the last few weeks of April, Clearview Resolution Services will be shutting ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who would like ... in a fraction of the time as traditional braces – Wilckodontics®. Dr. Victoria ... now offers this revolutionary treatment with or without a referral. , Wilckodontics ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest quality ... problems, I focus on preventative care with all my patients to alleviate possible future issues. ... feel free to contact my office and my trained staff will assist you in any ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... instrument solutions, announces the continuation of its strategic partnership with and platinum sponsorship ... developing nations in the safe and effective management of complex spine deformity cases, ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, Inc. ... healthcare, today announced that it will be participating in ... at the InterContinental Hotel in Boston, Massachusetts ... will present at 11:20 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... the Company,s consumer product development program, based on ... Society for Investigative Dermatology (SID) 76 th ... and promote the sciences relevant to skin health ...
Breaking Medicine Technology: